U.S. Biotech Stock News

NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

A Look At AGNC Investment (AGNC) Valuation After Recent Share Price Pullback And Tight Fair Value Estimate

AGNC Investment at a glance AGNC Investment (AGNC) has attracted attention after a recent pullback, with the share price at $9.69 and negative returns over the past month and past 3 months contrasting with a positive 1 year total return. See our latest analysis for AGNC Investment. Recent trading has been weak, with the 1 month share price return of AGNC Investment at a 13.56% decline and the year to date share price return at an 11.34% decline, even as the 1 year total shareholder return...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors

On 19 March 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal nerve stimulation therapy for adult patients with moderate to severe obstructive sleep apnea who cannot use or benefit from first-line treatments like positive airway pressure. Backed by the rigorously designed OSPREY randomized controlled trial and plans for an MRI‑compatible, rechargeable next‑generation device, this approval opens a new neuromodulation avenue for...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate

Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high risk patients with diabetes. The results indicate that Repatha, used alongside statins or other LDL C lowering therapies, may support earlier intervention for patients without diagnosed atherosclerosis. These findings position Repatha as the only PCSK9 inhibitor with evidence across both primary and secondary prevention settings. For...
NasdaqGS:GLDD
NasdaqGS:GLDDConstruction

A Look At Great Lakes Dredge & Dock (GLDD) Valuation After Strong Recent Share Price Momentum

Why Great Lakes Dredge & Dock (GLDD) is on investors’ radar today Great Lakes Dredge & Dock (GLDD) has drawn fresh attention after a period of strong longer term share performance, including a past 3 months total return of 29.1% and a 1 year total return of 91.9%. See our latest analysis for Great Lakes Dredge & Dock. At a share price of $16.97, recent momentum has come through a strong 90 day share price return of 29.2% and a 1 year total shareholder return of 92%, pointing to improving...
NYSE:OMF
NYSE:OMFConsumer Finance

Is OneMain Holdings (OMF) Pricing Look Attractive After This Year’s Share Price Pullback

If you are wondering whether OneMain Holdings at around US$51.55 is offering fair value or a potential bargain, it helps to step back and look at the full valuation picture before making any decisions. The stock shows mixed recent returns, with a 0.1% move over the last 7 days, a 6.3% decline over 30 days, a 25.4% decline year to date, a 14.9% gain over 1 year, 79.3% over 3 years, and 48.9% over 5 years. Recent news coverage around OneMain Holdings has largely focused on its position within...
NYSE:VG
NYSE:VGOil and Gas

Does Venture Global (VG) Still Offer Value After Its Recent Share Price Surge?

If you are wondering whether Venture Global's current share price reflects its real worth, this article walks through the key numbers behind the stock. Over shorter periods the stock has been active, with returns of 10.9% over 7 days, 80.9% over 30 days, 149.0% year to date and 77.3% over the last year. These movements can affect how investors think about both upside potential and risk. Recent attention around Venture Global has centered on its role in the energy sector and how investors are...
NYSE:S
NYSE:SSoftware

Assessing SentinelOne (S) Valuation After New Google Cloud And LevelBlue AI Security Partnerships

SentinelOne (S) has drawn fresh attention after announcing a multi-year collaboration with Google Cloud, a global partnership with LevelBlue, and new AI-focused security offerings showcased at RSA Conference 2026. See our latest analysis for SentinelOne. Despite the Google Cloud collaboration, LevelBlue partnership, and new AI offerings showcased at RSA, SentinelOne’s recent momentum has been weak, with a 90-day share price return of 16.3% and a 1-year total shareholder return of 33.2%. If...
NasdaqCM:BTBT
NasdaqCM:BTBTSoftware

Bit Digital (BTBT) Q4 Loss Of US$188 Million Tests Bullish Profitability Narratives

Bit Digital (BTBT) has just posted its FY 2025 numbers with Q4 total revenue of US$33.4 million and a basic EPS loss of US$0.58, set against trailing twelve month revenue of US$113.6 million and a TTM basic EPS loss of US$0.31. Over recent quarters the company has seen quarterly revenue move from US$25.6 million in Q4 2024 to US$33.4 million in Q4 2025. Basic EPS has swung between a loss of US$0.32 in Q1 2025 and a profit of US$0.48 in Q3 2025 before returning to a loss in Q4, leaving...
NasdaqGS:WIX
NasdaqGS:WIXIT

Has Wixcom (WIX) Rallied Too Far After Its Recent 23% Share Price Jump

If you are wondering whether Wix.com is attractively priced or still has more risk baked in than reward, the starting point is understanding what the current share price actually implies. The stock recently closed at US$87.14, after a sharp 23.7% gain over the last 30 days that sits against a 47.6% decline over the past year and a 70.3% decline over five years. That kind of rebound after a long stretch of weaker returns often comes after fresh information, such as changes in sentiment around...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly PsA Trial Links Dual Therapy Success With Valuation Upside Potential

Eli Lilly (NYSE:LLY) reported Phase 3b TOGETHER-PsA data showing that Taltz combined with Zepbound outperformed Taltz alone in adults with both active psoriatic arthritis and obesity. The trial represents the first time a dual-targeted approach has shown efficacy in this comorbid population, linking an immunology therapy with a metabolic drug in one regimen. The findings create a potential path toward label expansion for both medicines and may influence future treatment standards for...
NYSE:BMY
NYSE:BMYPharmaceuticals

A Look At Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Outperforms Recent GAAP Loss

Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) is drawing attention after recent share price moves, with the stock showing a mix of short term pressure and longer term resilience that invites a closer look at its fundamentals. See our latest analysis for Bristol-Myers Squibb. At a share price of US$58.54, Bristol-Myers Squibb has seen a 1 day share price decline of about 1.5%, alongside a 9.5% year to date share price return and a 12.6% five year total...
NYSE:ETR
NYSE:ETRElectric Utilities

Why Entergy (ETR) Is Up 10.0% After Meta Funds Its Louisiana Grid Expansion Plan

Earlier this month, Entergy Louisiana disclosed a major agreement under which Meta Platforms will finance ten natural gas plants, around 240 miles of high-voltage transmission lines, grid-scale battery storage, and nuclear uprates to power Meta’s Hyperion data center in rural Louisiana while covering its full cost of service. The deal’s structure, which is expected to deliver more than US$2.00 billion in ratepayer savings over two decades, highlights how tailored utility-customer...
OTCPK:KISB
OTCPK:KISBBanks

Kish Bancorp (OTCPK:KISB) Net Profit Margin Near 26% Reinforces Bullish Community Narratives

Kish Bancorp (KISB) just turned in its FY 2025 numbers with fourth quarter revenue of US$18.9 million and basic EPS of US$1.84, alongside trailing twelve month revenue of US$70.3 million and EPS of US$6.25 that frame the full year picture. Over the past few quarters, revenue has moved from US$15.8 million in Q3 2024 to US$18.9 million in Q4 2025, while quarterly EPS has gone from about US$1.39 to US$1.84. This sets up a results season where margins and earnings quality are front and center...
NYSE:COMP
NYSE:COMPReal Estate

Compass (COMP) Valuation Check After Recent Share Price Weakness

Compass (COMP) has been drawing fresh attention after recent trading left the stock with a year-to-date return of about a 33% decline and a past 3-month move of roughly a 34% decline. See our latest analysis for Compass. The recent 1-day share price return of a 7.09% decline and 30-day share price return of a 27.38% decline at a latest share price of $7.08 sit against a 3-year total shareholder return of 119.20%, which hints that recent momentum has faded compared with earlier gains. If...
NYSE:UWMC
NYSE:UWMCDiversified Financial

UWM Holdings Tests Governance Stance With Bid For Two Harbors Servicing

UWM Holdings (NYSE:UWMC) has publicly challenged the management and board of Two Harbors as part of its acquisition proposal. The company is openly criticizing how Two Harbors is overseen, while outlining its interest in the firm's mortgage servicing portfolio. This move highlights UWM Holdings' acquisition ambitions and puts its leadership approach and governance views in the spotlight. For readers watching NYSE:UWMC, this public challenge comes at a time when the stock trades at $3.42 and...
NYSE:PBT
NYSE:PBTOil and Gas

Permian Basin Royalty Trust (PBT) Net Margin Compression Tests Bullish Narratives

Permian Basin Royalty Trust FY 2025 Earnings Snapshot Permian Basin Royalty Trust (PBT) has put up a mixed set of numbers for FY 2025 so far, with third quarter revenue at US$7.3 million and basic EPS of US$0.15, compared with US$8.4 million of revenue and EPS of US$0.17 in the same quarter a year earlier. Across the last six reported quarters, revenue has ranged from roughly US$3.1 million to US$8.8 million, while quarterly EPS has moved between US$0.05 and US$0.18. This gives a clear view...
NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Assessing Whether Dave (DAVE) Shares Look Undervalued After Recent Volatility

Event context and recent share performance Dave (DAVE) has drawn investor attention after recent trading, with the stock last closing at US$174.95. The shares show a 2.3% decline over the past day and a 16.6% decline over the past week. See our latest analysis for Dave. While the recent 1-week share price return of a 16.6% decline and 90-day share price return of a 23.2% decline point to fading short term momentum, the 1-year total shareholder return of 106.9% and very large 3-year total...
NYSE:WCN
NYSE:WCNCommercial Services

Evaluating Waste Connections (WCN) Valuation After Recent Share Price Weakness

Why Waste Connections (WCN) Is On Investors’ Radar Recent share weakness in Waste Connections (WCN), including double digit negative returns over the past month and past 3 months, has turned more attention to whether the current price reflects its underlying fundamentals. See our latest analysis for Waste Connections. At a share price of US$156.02, Waste Connections has faced steady selling pressure recently, with a 30 day share price return of 9.36% and year to date share price return of...
NasdaqGS:TXN
NasdaqGS:TXNSemiconductor

TI’s New 800V AI Data Center Power Platform Might Change The Case For Investing In Texas Instruments (TXN)

Earlier this month, Texas Instruments introduced new IsoShield-based isolated power modules and an 800V DC power architecture for AI data centers, aimed at boosting power density, efficiency and safety in applications from EVs to next-generation computing. By tightly integrating transformers and power stages and showcasing designs alongside NVIDIA’s 800V reference platform, TI is underscoring its role in the power infrastructure underpinning AI data centers, advanced automotive systems and...
NYSE:JPM
NYSE:JPMBanks

Is It Time To Reconsider JPMorgan Chase (JPM) After Recent Share Price Weakness?

If you are trying to work out whether JPMorgan Chase at about US$282.84 is offering good value or asking too much, it helps to break the story into what the market has been pricing in and what the fundamentals might support. The stock has seen a 1.3% decline over the last 7 days and a 5.8% decline over the last 30 days, while still showing a 13.1% decline year to date and an 18.9% return over the last year, with very large gains over 3 and 5 years of 133.0% and 109.0% respectively. Recent...
NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

Does SIGA (SIGA)’s Repeat Special Dividend Reveal a Deeper Shift in Its Capital Allocation Priorities?

SIGA Technologies, Inc. recently announced that its board declared a special cash dividend of US$0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. The company linked this repeat special dividend to its strong balance sheet and its ongoing work with governments on smallpox preparedness amid geopolitical volatility. We’ll now examine how this repeat US$0.60 special dividend and the company’s emphasis on balance sheet strength shape SIGA’s investment...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

Is It Too Late To Consider IDEAYA Biosciences (IDYA) After Its Strong Multi Year Run

If you are wondering whether IDEAYA Biosciences at around US$30.46 is still offering value after a strong run, the key is to separate story from price. The stock has returned 78.7% over the past year and 121.8% over three years, even though the year to date move is a 10.0% decline, with 7 day and 30 day returns of 7.0% and 5.4% declines. Recent coverage has focused on IDEAYA Biosciences as a biotech name that has already delivered strong multi year gains while still experiencing short term...
NYSE:AFL
NYSE:AFLInsurance

A Look At Aflac (NYSE:AFL) Valuation After New Long Term Care Rider And Distribution Collaboration

Aflac (AFL) has drawn fresh attention after adding a long term care rider to its Group Life Term to 120 policy, aligning its product lineup with rising care needs among aging Americans. See our latest analysis for Aflac. Despite the new long term care rider and recent governance debates around separating the CEO and chair roles, Aflac’s 30 day share price return of a 5.8% decline and year to date share price return of a 3.5% decline contrast with a much stronger 3 year total shareholder...
NYSE:MC
NYSE:MCCapital Markets

Assessing Moelis (MC) Valuation After Recent Share Price Weakness

Moelis stock reaction and recent performance snapshot With no single headline event driving Moelis (MC) today, the current share price around US$54.28 and recent performance provide a reference point for thinking about risk, return, and timing. Over the past month the stock shows a return of about a 9% decline, with the past 3 months closer to a 24% decline, while the 1 year total return is roughly a 2% decline. Over the longer term, 3 year and 5 year total returns of about 62% and 31%...